The cystic fibrosis (CF) gene encodes a cAMP-regulated chloride channel, the CF transmembrane conductance regulator (CFTR). CFTR Inhibitor-172 is a thiazolidinone that selectively blocks the CFTR channel (Ki = 300 nM) in a voltage-independent manner. It appears to directly modulate the gating of chloride at the channel and does not prevent elevation of cAMP or inhibit other pumps or channels. In mice, CFTR inhibitor-172 prevents cholera toxin-induced fluid secretion in the small intestine, when given by intraperitoneal injection. It slows cyst growth in animal models of polycystic kidney disease. As CFTR also modulates glutathione (GSH) efflux, CFTR inhibitor-172 can affect intracellular GSH concentration and reactive oxygen species balance.
CFTR(inh)-172 has been used to specifically inhibit cystic fibrosis transmembrane conductance regulator (CFTR) activity. It is also used as a CFTR inhibitor Inh-172 to treat forskolin and IBMX.
ChEBI: A thiazolidinone that is 2-thioxo-4-thiazolidinone which is substituted at position 3 by a (m--trifluoromethyl)phenyl group and at position 5 by a p-carboxybenzylidene group. It is an inhibitor of cystic fibrosis transmembrane con
uctance regulator, a membrane protein and chloride channel in vertebrates that is encoded by the CFTR gene.
Voltage-independent, selective CFTR chloride channel blocker (K i = 300 nM) that alters channel gating. Blocks intestinal fluid secretion induced by cholera toxin and Escherichia coli and suppresses cyst growth in animal models of polycystic kidney disease. Orally active. Inhibits mitochondrial respiration and increases reactive oxygen species (ROS) production independently of CFTR in several cell lines.
CFTR(inh)-172 is an inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR). With a Ki = 300 nM,. CFTR(inh)-172 leads to rapid, reversible and voltage-independent inhibition; it is an antidiarrheal agent in animals. CTFR(inh)-172 may be a useful tool to study animal models of cystic fibrosis and intestinal fluid loss in cholera and other secretory diarrheas. CTFR(inh)-172 is structurally-unrelated to known, but non-specific CFTR inhibitors DPC, NPPB (Cat. No. N4779) and Glibenclamide.
Using 2-thio-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-one (55 mg, 0.2 mmol) and p-formylbenzoic acid (30 mg, 0.2 mmol) as the raw material, a few drops of piperidine were added as a catalyst in anhydrous ethanol (0.5 ml), and the reaction was carried out by refluxing the mixture for 2 hours. Upon completion of the reaction, the solvent was removed by evaporation and the residue was purified by ethanol crystallization and further purified by normal-phase fast chromatography to afford 54 mg of the yellow powdery product 3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylidene]-2-thiazolidine-4-thiazolidinone (67% yield), with a melting point of 180-182 °C. The structure of the product was confirmed by 1H NMR and mass spectrometry: 1H NMR (DMSO-d6) δ 13.20 (bs, 1H, COOH, D2O exchanged), 8.07 (d, 2H, carboxyphenyl, J = 8.31 Hz), 7.80-8.00 (m, 5H, trifluoromethylphenyl and CH), 7.78 (d, 2H, carboxyphenyl, J = 8.2 Hz) ; MS (ES-) m/z: [M-1]- Calculated value 408.40 (C18H9F3NO3S2), measured value 408.23.
cftrinh-172 could reversibly inhibit cftr short-circuit current in less than 2 minutes in a voltage-independent manner. moreover, at concentrations fully inhibiting cftr, cftrinh-172 did not prevent elevation of cellular camp or inhibit non-cftr cl–channels, multidrug resistance protein-1, atp-sensitive k+ channels, or a series of other transporters [2].
a single ip injection of cftrinh-172 (250 μg/kg) in mice reduced by more than 90% cholera toxin–induced fluid secretion in the small intestine over 6 hours. cftrinh-172 may be useful in developing large-animal models of cystic fibrosis and reducing intestinal fluid loss in cholera and other secretory diarrheas [3].
[1] ma t, thiagarajah jr, yang h, sonawane nd, folli c, galietta lj, verkman as. thiazolidinone cftr inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. j clin invest. 2002 dec;110(11):1651-8.
